Tools for Practice: Jeopardy Edition. Mike Allan (part of the) ACFP Evidence & CPD Team

Size: px
Start display at page:

Download "Tools for Practice: Jeopardy Edition. Mike Allan (part of the) ACFP Evidence & CPD Team"

Transcription

1 Tools for Practice: Jeopardy Edition Mike Allan (part of the) ACFP Evidence & CPD Team

2 Guidelines Presenter Disclosure: G Michael Allan has no potential for conflict of interest with this presentation He wrote or was the editor for these Tools for Practice. The Tools for Practice is sponsored by a grant from the Alberta College of Family Physicians

3 Jeopardy AOM & small miracles All Benefit, No harm Hormones The Bell Tolls Lot Clot OCP? HDL Cure-All Best Thiazide Diet Vs Health BMD tests Lubricant wrecks a PAP test Old Iron Doses TCA 4 Smoking Exercise 2 4-letter words Need a little, take a lot OTC (antihistamines) for cold Coffee: Nice Vice Dual Anti-platelet: To Stop or not Omega-3: Igloo Fix Fasting?: A1c Dx Need a little, take a multi-lot Delaying Abx Burning for a UTI answer Osteoporosis Screening Test Calcium: +/-/= Flashes of Evidence Menopause Insulin: Is longer better Bisphosphonates To infinite &, Paediatric Fever: If yes, what drug Hold on Honey: Cough Ezetimibe: still waiting Elderly BP: careful Start Insulin at the end Old #1: Atenolol

4 Amoxil will help 1 in 4 young kids with AOM? Evidence: 2 RCTs & a systematic review. Avoid treatment failure day 8-12: NNT 3-9 Adverse events up: particularly diarrhea (NNH 5-7) At 7-14 days, AOM will resolve in approximately 70% untreated children. Poor Prognostic: Bilateral AOM, age <24 months, exposure to more children (day-care), and more severe symptom scores Bottom-line: Although most children will recover from Acute Otitis Media without complications, antibiotics will improve outcomes for 1 in 3 to 1 in 10, depending on outcome and complicating factors. They will cause adverse events, particularly diarrhea, in up to 1 in every 5. #42 Feb 22, 2011

5 Do antiviral medications provide any benefit to patients with Bell s Palsy? Evidence: Meta-analysis, 2 high-quality RCTs Unsatisfactory recovery at 4 months: corticosteroid 16% vs Placebo 26% (NNT 10) Antivirals, with or without steroid, no additional benefit Bottom-line: The best evidence indicates that corticosteroids (in doses of prednisolone 25 mg BID or 60 mg x5 days then tapered by 10 mg/day) improve the odds of complete recovery from Bell s Palsy. Antivirals (used either alone or in addition to prednisolone) seem to offer no advantage (although research continues in severe Bell s Palsy). #4 July 9, 2009 Updated July 8, 2013

6 Newer Contraceptive have a clearly higher risk of Venous Thromboembolism (VT)? Evidence: cohort studies 4-5/10,000 for non-users or progestin only 10/10,000 for older OCP (like levonorgestrel).1,7 20/10,000 for transdermal or vaginal ring, newer OCP8 29/10,000 for pregnancy (for comparison).1 Bottom-line: Due to limits in the evidence, there is real uncertainty whether the risks of VT vary with different hormonal contraceptives. If they do, the increased risk appears to be about 1 extra VT per year for 2000 women. #70 July 23, 2012

7 Adding Niacin to statins has a small benefit in patients with CVD (+ low HDL levels)? Evidence: AIM-HIGH, 3-yr RCT 3414 patients (and new 25,000 pt Merck trial stopped early) Still, niacin may be better than ezetimibe Bottom-line: In patients with cardiovascular disease already on statin therapy, adding niacin does not improve cardiovascular events. Among lipid treatments, only statin monotherapy has strong evidence for CVD prevention (regardless of lipid levels). #65 April 10, 2012

8 Bioidentical hormone micronized progesterone has lower risks vs synthetic medroxyprogesterone? Evidence: RCTs of surrogate markers. Cohorts of without results or multiple flaws, and surveys. Compounding compounds uncertainty. Bottom-line: The theory behind bioidentical hormone use is appealing; however its clinical advantage is not supported by reliable evidence. Long-term safety is largely unknown. #63 March 5, 2012

9 When choosing a thiazide diuretic for hypertension, is hydrochlorothiazide (HCTZ) the best choice? Evidence: Meta-analysis showing Chlor > HCTZ NNT over 5 yrs (even when office BP same) BP (24 hour 5-7mmHg) better, MRFIT, all best trials Bottom-line: The available data suggest that chlorthalidone is at least equal to and very likely superior to HCTZ in reducing BP and improving clinical outcomes. Consider prescribing chlorthalidone (12.5mg increasing to 25mg daily) when initiating thiazide diuretic therapy for hypertension. #61 February 6, 2012; Hypertension. 2012;59(6):

10 Is any diet better for weight loss or preventing -ve health outcomes like heart disease or mortality? Evidence: No difference in low vs high carb, No evid: DASH, very low cal ( 800 cal), & cohort wgt loss Med diet: CVD NNT 12-14, mortality NNT 25 x2-3 yrs Bottom-line: Weight loss for all diets is best at 6 months, regain is common, and by two years there is no consistent difference between diets. Only the Mediterranean diet has demonstrated positive results in hard outcomes like mortality, despite not having differences in weight or surrogate markers like lipid profiles. #46 April 18, 2011

11 Once we have initiated bisphosphonate therapy, how frequently should we check bone mineral density (BMD)? Evidence: Too much variance for frequent testing Over 2 weeks, BMD variance = 2.4-5% Over 3 yrs BMD improves on Tx by 1-6%. Bottom-line: Repeating BMD in the first three years after starting treatment with a bisphosphonate is unnecessary and potentially confusing. The vast majority of patients taking a bisphosphonate will get an adequate increase in BMD after three years and have a reduced fracture risk regardless of BMD changes. #32 September 8, 2010

12 Does Lubricant disrupt the cytology of a PAP test? Evidence: 4 RCTs Lubricant has no effect on the cytology quality. Liquid based studies also find little effect One study found applying a cm 'ribbon' of lubricant gel directly to the cervical os might disrupt the cytology 2 studies show reduced pain/discomfort with lubricant Bottom-line: A small amount of water soluble lubricant on a speculum does not reduce the quality of the PAP test and probably does not affect microbiologic results either. The present evidence suggests the adequacy of liquid-based PAP tests would be minimally affected or not at all. #21 April 22, 2011

13 In elderly adults with iron deficiency anemia, what is the appropriate dose of iron? Evidence: 15 vs 150mg elemental iron = Hgb (14) Drop-out NNH 5, Abdo cramps or N/V=2, constipation=5 Ferrous Sulfate 300mg = elemental iron Bottom-line: In elderly patients with iron deficiency anemia, low doses of iron raise hemoglobin similar to higher doses with considerably less adverse events in most patients. Options for dosing include ½ of a 300mg ferrous gluconate per day or 2.5ml of Fer-In-Sol syrup a day. Clinicians should work-up the cause of anemia as appropriate. #30 July 6, 2010

14 In patients ready for smoking cessation, how effective are first-line medications and what are the potential concerns? Evidence: Assuming 10% placebo cessation rates: NTT: Varenicline 8, nortriptyline 10, bupropion 10, NRT 16 Buproprion 150mg 300mg; Varenicline: 0.5mg 1mg BID Nortriptyline: 25mg qhs, 25 mg q3-4d, mg max Bottom-line: In addition to nicotine replacement, buproprion, nortriptyline (off-label) and varenicline are all effective in smoking cessation, perhaps the latter more so. Adverse events vary and may in part relate to quitting smoking, but are important and require monitoring. #27 May 26, 2010

15 How do I motivate my patients to participate in regular physical activity? Evidence: 2 Sys Rev + RCTs: steps/day. Also reduce BP, Weight, glucose at $30/pedometer. Bottom line: Pedometers, used with specific exercise goals, provide an inexpensive, tangible measure of a patient s physical activity, and have been demonstrated to increase physical activity levels at least in the short term. #5 July 14, 2009

16 How do I motivate my patients to participate in regular physical activity? 1 Wear your pedometer every day for 1 week. 2 Calculate your daily steps. 3 Add 500 steps per day to your daily average. Walk that each day for the next week. 4 Repeat step 3, adding 500 steps to last week s daily goal, and walk that each day for the next week. 5 Continue until you reach steps per day. #5 July 14, 2009

17 Does daily supplementation with antioxidant vitamins (A, E and C) decrease mortality in the general population? Evidence: Meta-analysis with 296,707 patients Beta-carotene (pro-vitamin A): RR 1.05 ( ) Vitamin E (RR 1.03, ) Vitamin A all doses (RR 1.07, ) High dose vitamin A (? 5000IU) does increase mortality (p=0.002) NNH likely over 3.5 years or so. Bottom-line: The current evidence does not support the use of antioxidant supplementation, and patients should be dissuaded from using beta-carotene, vitamin E and perhaps high dose vitamin A, as they appear to increase mortality. #10 September 22, 2009 Updated June 28, 2013

18 Do antihistamines (alone or combo) improve cold Sx? Evidence: 3 Systematic rev (mostly moderate to poor RCTs) Antihistamine alone: no meaningful effect. Antihistamine with decongestants and/or decongestants improved global symptoms NNT 4-7. Limited evidence of benefit in peds Antihistamines and cold and cough preparations are 2nd and 6 th most common substances involved in (age 5 years) pediatric deaths. Bottom-line: Antihistamines alone have no meaningful impact on the common cold. Although evidence is at moderate to high risk of bias, antihistamines combined with decongestants and/or analgesia may have a small impact on improving symptoms for one in 4-7 patients but should not be used in children under 6. #80 January 7, 2013

19 Does drinking coffee impact mortality or other health outcomes in the general population? Evidence: 400,000 (US) x 14 yrs (+ other cohorts) Increased mortality with coffee (but lots of confounders) Men: About 10% relative reduction for 2 cups/day Women: About 15% relative reduction for 2 cups/day Bottom-line: Coffee consumption is associated with no change or a small reduction in mortality in cohort studies. While the evidence is not strong enough to recommend non-drinkers to start consuming coffee, coffee drinkers can be reassured that it does not appear to result in excess harm (except in pregnancy). #74 October 1, 2012

20 In CAD with stent placement or ACS, should dual antiplatelet therapy, like clopidogrel plus ASA, >12 months? Evidence: 12 vs months, 2-RCTs, 2701 pts Increased MI, stroke & death (12 months 1.3% vs months 2.7%, p=0.048). Meta-analysis cohort: no clear benefit beyond 12 months. Bottom-line: Current evidence and guidelines suggest that it is reasonable to continue dual antiplatelet therapy for 12 months following stent placement or acute coronary syndrome. After 12 months, one antiplatelet (example clopidogrel) may be stopped and low-dose ASA continued. #72 September 4, 2012

21 Do omega-3 fatty acid supplements reduce the risk of recurrent CVD in patients with existing CVD? Evidence: 3 RCTs ( ): No effect Meta-analysis (20,000): No effect RCT 12,000 diabetics (60% with CVD): no effect Bottom-line: Although guidelines recommend increased dietary omega-3 consumption, evidence does not support using omega-3 fatty acid supplements to prevent recurrent CVD events in patients with cardiovascular disease. #69 July 3, 2012

22 What are the advantages and disadvantages of using A1c as a diagnostic test for Type II DM? Evidence: A1c predicts outcomes fasting glucose Screening A1c Dx agreement: 22-33% fasting & OGTT A1c 6.5%: sensitivity and specificity = 44% and 79%, Bottom-line: While Hemoglobin A1c can be used for diagnosis of diabetes, controversy remains around appropriate cut-offs and agreement with other tests. Using the 6.5% cut-off recommended by the American Diabetes Association and the WHO may give inconsistent results from other glucose tests. #68 June 11, 2012

23 Daily multivitamins reduce mortality? Evidence: Meta-analysis of 21 RCTs (91,074 patients) x3.5 years. Most are primary prevention studies from Europe or North America. No effect on overall mortality: RR 0.98 ( ) No effect on cancer mortality: RR 0.96 ( ) No effect on CVD mortality: RR 1.01 ( ) Bottom-line: Present evidence does not support the routine use of multivitamins to reduce mortality, cardiovascular disease or cancer for people in developed countries. #87 April 15, 2013

24 What are the advantages and limitations of delayed prescriptions of antibiotics for URTI? Evidence: Meta-analysis of 9 RCTs Filled scripts: 32% delayed vs 93% immediate. Filled scripts for no antibiotics was 14% Delayed scripts slight reduce pt satisfaction (87% vs 92%) Bottom-line: Delayed antibiotic prescriptions versus immediate prescriptions substantially reduce antibiotic use but may slightly worsen some symptomatic outcomes. Delayed prescriptions may also reduce return to care rates and for mild URTI, are not associated with important negative consequences. #53 October 3, 2011

25 Does Cranberry juice or extract prevent recurrent urinary tract infections (UTI)? Evidence: 2 Systematic Rev & 1 additional RCT One no diff & another found NNT 12 (but only if excluded negative study) TMP-SMX (40/200 mg daily) or ciprofloxacin (125 mg daily), generally for 6 to 12 months. NNT =2 to 3 /yr. Bottom-line: Available evidence does not support cranberry products for reduction of UTIs. The overall quality of evidence is poor. #84 4 March 2013

26 What is the most efficient way to determine who is at high risk of osteoporosis and requires BMD? Evidence: 4 systematic reviews, up 72,000 women OST as good or better than all others Simple application of OST: Age - Weight (kg) If > -5, increased risk of osteoporosis, BMD is warranted. A cut-off of >5 should be used for Asian patients. Bottom-line: The OST is simple, quick and predicts osteoporosis as reliably as other more complicated instruments. It is a reasonable screening tool to identify those who would benefit from bone mineral density testing. #44 March 21, 2011

27 Does calcium (Ca+) supplementation contribute to increased risk of MI and other CVD? Evidence: Sys Rev 15 RCT Calcium increased MI risk: RR 1.27 ( ) NNT 135 to 211 x4 years. Others find no effect or NNT 240 (x5yr) Bottom-line: The present evidence suggests that calcium supplementation, particularly 1000mg/day, may lead to an increase risk of MI. This evidence is poor and the risk, if present, is likely <1%. #21 February 7, 2011

28 Hot flash treatment with SSRI as good as HRT? Evidence: Well-designed Meta-analysis of 43 RCT s SSRI/SNRI (mid dose)= 1.13 Hot Flashes/d (vs placebo) Clonidine ( 0.075mg BID) = Hot flashes/d Gabapentin (300mg TID) = 2.05 Hot flashes/d Soy Isoflavone Extract (50-70mg/d)= Endometrial safety with Isoflavone still unresolved. Estrogen best (2.5-3 Hot flashes/d) Bottom-line: All drugs for hot flashes are generally equivalent in effectiveness except HRT which is better. Select based on side-effects and patient preference. JAMA 2006; 295:

29 In diabetics, how do the long-acting insulin analogues (glargine and detemir) compare to NPH? Evidence: Sys Rev 49 RCT, A1c similar (? NPH lower) Severe hypoglycemia no diff, Some diff in nocturnal or overall (NNT 7-12) BUT hypo not confirmed, blinded, or specific Bottom-line: Compared to NPH insulin, long-acting insulin analogues have no advantage in A1c, no evidence for hard outcomes, and no difference in severe hypoglycemia. The small reductions in other hypoglycemic symptoms have a high risk of bias. #35 October 26, 2010

30 Can osteoporosis patients on bisphosphonates for 5 yrs d/c meds without increasing future fracture risk? Evidence: FLEX RCT, bisphosphonate x 5 yrs, off 5 yrs No difference in fractures HORIZON-Pivotal Fracture Trial (PFT) Extension: Zoledronic Also, no effect on preventing fractures. Bottom-line: Available evidence suggests that after 5 years of treatment, discontinuation of bisphosphonates carries little to no increased future fracture risk. Choosing appropriate patients to continue therapy beyond 5 years and determining when or if to reinitiate therapy in those discontinued, remains uncertain. #33 September 20, J Bone Miner Res Feb;27(2):

31 When recommending regarding paediatric fever treatment, is acetaminophen or ibuprofen superior? Evidence: Meta-analysis of 10 trials, Ibuprofen superior at 2, 4, and 6 hours; NNT 7 RCT: ibuprofen, acetaminophen, or both combo fever in 24 hrs vs Aceta 4.4 hrs more, ibu 2.5 Bottom-line: Treatment of paediatric fever is debated and should be discussed with parents/patients. If clinicians are going to recommend a treatment, ibuprofen offers superior fever reduction with no increase in adverse events. #28 June 7, 2010

32 Do OTC cough suppressants or Honey improve cough due to URTI in children? Evidence: 3 RCTs if Honey, all find the same At 24 hrs: 59% honey, 45% DM and DPH, 31% no-drug 8 RCTs with 616 children: No effect Health Canada recommends against OTC cough in <6 Bottom-line: OTC cough suppressants should not be used in children under 6 and do not appear to be effective in older children. There is sufficient evidence to consider the use of honey in acute pediatric cough. #24 April 12, 2010

33 Does Ezetimibe (Ezetrol) modify clinical outcomes? Evidence: Trials: Enhance, Arbiter-Halts, SEA, SHARP, Improve-IT* Combo: statin + Ezetimibe vs nothing, useless study Ezetimibe vs placebo (background statin): No effect Inferior to niacin (5% CVD vs 1%). Also? cancer Bottom-line: Eight years after being licensed by the FDA, there is still no evidence that ezetimibe reduces cardiovascular outcomes. It may be worse than niacin and there is concern about a potential increased cancer mortality risk. #23 March 29, 2010

34 In patients over age 80, what are risks and benefits of treating hypertension (& different targets)? Evidence: RCT 3845 pts x 2.1 yrs, BP > 160 Outcomes: mortality - NNT 47, CVD - NNT 34 Healthy: ( 12% CVD history, < 7% DM, no dementia) RCT, 3260 patients, aged 70-84, <150 = <140 mm Hg. Bottom-line: Treating hypertension in healthy elderly patients age 80 is effective. Exact targets are uncertain but the primary trial used 150/90 as a target. The benefit of treating the frail elderly or those with orthostasis and/or a standing systolic pressure of <140 remains uncertain. #22 March 15, 2010

35 What is the optimal regimen for initiating insulin in type 2 diabetes? Evidence: 4 RCTs (primarily 1 or 708 pts x 3 yrs) A1C similar but basal has less hypo & wgt gain Family Doctors just as effective with A1c Basal NPH, 10 units qhs, add 1 unit qhs, until fasting 4-7 Bottom-line: In type 2 diabetes poorly controlled with oral agents, initiating basal insulin results in similar HbA1c reductions compared to prandial or biphasic insulin and may cause less weight gain and hypoglycemia. Family practitioners who start insulin are as effective as specialists. #20 February 16, 2010

36 Are beta-blockers, particularly atenolol, equal to other antihypertensive meds in preventing hypertensive outcomes? Evidence: Atenolol, meta-analysis, 5 RCT No effect vs placebo Vs other meds: more strokes (NNH 79), deaths (NNH 110) Other Beta-blockers: Less clear,? Worse if older. Bottom-line: Atenolol is an inferior choice for blood pressure treatment. Beta-blockers in general should not be considered first line in age 60 and some have suggested they should not be first line in any patient with uncomplicated hypertension. #15 November 30, 2009

37 End

Conflict of Interest. The Tools for Practice 22/11/2012. Family Doctor x 15 years Academic x 10 years

Conflict of Interest. The Tools for Practice 22/11/2012. Family Doctor x 15 years Academic x 10 years G Michael Allan, Associate Professor Conflict of Interest Family Doctor x 15 years Academic x 10 years Pay from U of A and Alberta Health Research and Speaking Fees Non Profit Sources (Alberta College

More information

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated

More information

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,

More information

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic 1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker

More information

What s New, What s True, and What s Poo Part 1

What s New, What s True, and What s Poo Part 1 What s New, What s True, and What s Poo Part 1 Tina Korowynk and Mike Kolber PEER Group What s New? What s True? What s Poo? 1 Anti-Depressants Meta-Analysis (Network): 522 RCTs (116477 pts) Mean duration

More information

The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)

The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division

More information

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

ADVANCES IN MANAGEMENT OF HYPERTENSION

ADVANCES IN MANAGEMENT OF HYPERTENSION Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%

More information

HRT & Menopause Where Do We Stand Now?

HRT & Menopause Where Do We Stand Now? HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by

More information

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Managing Hypertension in 2016

Managing Hypertension in 2016 Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu

More information

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College

More information

Managing menopause in Primary Care and recent advances in HRT

Managing menopause in Primary Care and recent advances in HRT Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims

More information

Managing menopause in Primary Care and recent advances in HRT

Managing menopause in Primary Care and recent advances in HRT Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway

More information

New, True & Poo. Faculty/Presenter Disclosure

New, True & Poo. Faculty/Presenter Disclosure New, True & Poo Unpleasant Truths Comforting Lies Tina, Mike K, Adrienne, Mike A, Evidence & CPD Program, Alberta College of Family Physicians Department of Family Medicine, University of Alberta Faculty/Presenter

More information

Preventing and Treating High Blood Pressure

Preventing and Treating High Blood Pressure Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018 Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma

More information

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and

More information

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016 Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

Update in Hypertension

Update in Hypertension Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE? MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals

More information

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for

More information

Disclosure. Overview. Objectives. Five Noteworthy Outpatient Publications. Factors Affecting Antibiotic Prescribing 7/24/2013

Disclosure. Overview. Objectives. Five Noteworthy Outpatient Publications. Factors Affecting Antibiotic Prescribing 7/24/2013 47 th Annual Meeting August 2-4, 2013 Orlando, FL Five Noteworthy Outpatient Publications R. Vandervoort, Pharm.D. Disclosure I do not have a vested interest in or affiliation with any corporate organization

More information

Managing Back Pain. Faculty/Presenter Disclosure

Managing Back Pain. Faculty/Presenter Disclosure Managing Back Pain G. Michael Allan Evidence & CPD Program, Alberta College of Family Physicians Professor, Dept Family Med, U of A. Faculty/Presenter Disclosure Faculty/Presenter: G. Michael Allan Relationships

More information

The Latest Generation of Clinical

The Latest Generation of Clinical The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform

More information

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Top 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008

Top 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Top 5 (Topics) Papers In GIM 2008 Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Methods Searched ACPJC/EBM, TOC of top medical journals, MEDSCAPE Best Evidence, consultation

More information

Menopause management NICE Implementation

Menopause management NICE Implementation Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not

More information

DINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC

DINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD

More information

Coronary Artery Disease Clinical Practice Guidelines

Coronary Artery Disease Clinical Practice Guidelines Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.

More information

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

OSTEOPOROSIS: PREVENTION AND MANAGEMENT OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring

More information

Misperceptions still exist that cardiovascular disease is not a real problem for women.

Misperceptions still exist that cardiovascular disease is not a real problem for women. Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees

More information

Update in the Literature 2012

Update in the Literature 2012 Update in the Literature 2012 Mel L. Anderson, MD, FACP Chief, Hospital Medicine Section Associate Chief, Medical Service Denver VA Medical Center Associate Professor of Medicine University of Colorado

More information

Menopausal hormone therapy currently has no evidence-based role for

Menopausal hormone therapy currently has no evidence-based role for IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),

More information

HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer

HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Supplemental Table 1. Distribution of Participants Characteristics by Treatment Group at Baseline - The Vitamin D and calcium (CaD) Trial of the Women s Health Initiative (WHI) Study,

More information

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice. Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN 1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification

More information

Hypertension Pharmacotherapy: A Practical Approach

Hypertension Pharmacotherapy: A Practical Approach Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.

More information

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014 HYPERTENSION IN THE ELDERLY A BALANCED APPROACH Barry Goldlist October 31, 2014 DISCLOSURE I have not accepted any money for myself from any pharmaceutical company in the 21 st century I have accepted

More information

First line treatment of primary hypertension

First line treatment of primary hypertension First line treatment of primary hypertension Dr. Vijaya Musini Assistant Professor, Dept. Anesthesiology, Pharmacology and Therapeutics Manager, Drug Assessment Working Group Therapeutics Initiative Editor,

More information

APPENDIX D: PHARMACOTYHERAPY EVIDENCE

APPENDIX D: PHARMACOTYHERAPY EVIDENCE Página 1 de 7 APPENDIX D: PHARMACOTYHERAPY EVIDENCE Table D1. Outcome Trials of Antihypertensive Agents Study Drug Regimen N Duration Primary Outcomes Remarks Antihypertensive Therapy vs Placebo SHEP 1991

More information

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help

More information

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015 Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor

More information

Modern Management of Hypertension

Modern Management of Hypertension Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence

More information

Bone and Calcium Outcome

Bone and Calcium Outcome Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children: Bone and Calcium Outcome D R. C O N N I E W E A V E R D E PA R T

More information

Coordinator of Post Professional Programs Texas Woman's University 1

Coordinator of Post Professional Programs Texas Woman's University 1 OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic

More information

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018 Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Placebo-Controlled Statin Trials Prevention Of CVD in Women MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of

More information

Management of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE

Management of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE Management of DM in Older Adults: It s not all about sugar! Peggy Odegard, Pharm.D., BCPS, CDE Who needs treatment for DM? 87 year old, frail male with moderately severe dementia living in NH with persistent

More information

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode

More information

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE

More information

Before you prescribe

Before you prescribe Initiating hormone replacement therapy (HRT) / menopausal hormone therapy (MHT) Dr Sonia Davison Jean Hailes Consultant Endocrinologist Before you prescribe Ensure there are no contraindications to HRT/MHT

More information

American Diabetes Association 2018 Guidelines Important Notable Points

American Diabetes Association 2018 Guidelines Important Notable Points American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating

More information

Modern Management of Hypertension: Where Do We Draw the Line?

Modern Management of Hypertension: Where Do We Draw the Line? Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure

More information

Hot off the press. What s new and potentially relevant. Petr Polasek MD FRCPC FACC

Hot off the press. What s new and potentially relevant. Petr Polasek MD FRCPC FACC Hot off the press What s new and potentially relevant Petr Polasek MD FRCPC FACC Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf

Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf Disclosure None Polypill & CVD Prevention 1. Why do we need a polypill? 2. What components in the polypill?

More information

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Long-Term Complications of Diabetes Mellitus Macrovascular Complication Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent

More information

MENOPAUSAL HORMONE THERAPY 2016

MENOPAUSAL HORMONE THERAPY 2016 MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.

More information

Nutraceuticals and Cardiovascular Disease: Are we fishing?

Nutraceuticals and Cardiovascular Disease: Are we fishing? Nutraceuticals and Cardiovascular Disease: Are we fishing? ACC Rockies 2013 March 20,2013 Sheri L. Koshman BScPharm, PharmD, ACPR Assistant Professor, Division of Cardiology, University of Alberta sheri.koshman@ualberta.ca

More information

Treat-to-Target Tools

Treat-to-Target Tools TEAMcare Care Manager Primary Care Provider Treat to Target Discussion Tool for Treatment Enhancement Activation and Motivation (TEAM) Depression, Diabetes and Coronary Heart Disease (CHD) Intervention

More information

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research

More information

Introduction: Case One. Commonly used agents 4/10/2015

Introduction: Case One. Commonly used agents 4/10/2015 Introduction: Rates of herbal medications Source NHANEs 2007 17.9% current users PMID: 22030445 Surgical population 57% of population were ever users, PMID: 16% current users 15051013 Non-pregnant rural

More information

Clinical Practice Guideline

Clinical Practice Guideline Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)

More information

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial 1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.

More information

Pharmacotherapy for Tobacco Dependence Treatment

Pharmacotherapy for Tobacco Dependence Treatment Pharmacotherapy for Tobacco Dependence Treatment Nancy Rigotti, MD Professor of Medicine, Harvard Medical School Director, Tobacco Research and Treatment Center, Massachusetts General Hospital nrigotti@partners.org

More information

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC

UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC UPDATES IN AMBULATORY MEDICINE ERIK RIESSEN, MD, FACP INTERMOUNTAIN MEDICAL CENTER OUTPATIENT INTERNAL MEDICINE RESIDENCY CLINIC DISCLOSURES: I have no conflict-of-interest disclosures UPDATES: THE STRUGGLE

More information

Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14

Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Disclosures Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance

More information

:{ic0fp'16. Geriatric Medicine: Optimal Heart Health Amid Changing Guidelines. (and the Evidence for When to Stray) Kevin Overbeck, DO

:{ic0fp'16. Geriatric Medicine: Optimal Heart Health Amid Changing Guidelines. (and the Evidence for When to Stray) Kevin Overbeck, DO :{ic0fp'16 ACOFP 53 rd Annual Convention & Scientific Seminars Geriatric Medicine: Optimal Heart Health Amid Changing Guidelines (and the Evidence for When to Stray) Kevin Overbeck, DO Optimal Heart Health

More information

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured. Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.

More information

TEAMcare Treat-to-Target Tools

TEAMcare Treat-to-Target Tools TEAMcare Treat-to-Target Tools The TEAMcare Treatment Discussion Tool (treatment protocol) Nurse Case Manager (NCM)-MD Treat-to-Target Discussion Tool for Treatment Enhancement Activation and Motivation

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

MEDICATION APPROPRIATENESS FOR THE AGING POPULATION. Building Partnerships for Successful Aging

MEDICATION APPROPRIATENESS FOR THE AGING POPULATION. Building Partnerships for Successful Aging MEDICATION APPROPRIATENESS FOR THE AGING POPULATION Building Partnerships for Successful Aging Learning objectives Appreciate complexities involved in making appropriate clinical decisions in older adults

More information

Page 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis

Page 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s

More information

American Diabetes Association: Standards of Medical Care in Diabetes 2015

American Diabetes Association: Standards of Medical Care in Diabetes 2015 American Diabetes Association: Standards of Medical Care in Diabetes 2015 Synopsis of ADA standards relevant to the 11 th Scope of Work under Task B.2 ASSESSMENT OF GLYCEMIC CONTROL Recommendations: Perform

More information

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu

More information

Jared Moore, MD, FACP

Jared Moore, MD, FACP Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner

More information

Diagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis

Diagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology

More information

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,

More information

Osteoporosis Update. Greg Summers Consultant Rheumatologist

Osteoporosis Update. Greg Summers Consultant Rheumatologist Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o

More information